Hanool Meropenem Injection 1g (Meropenem Trihydrate)

Adult administration

Administer 0.5 to 1 g (potency) of meropenem hydrate divided into 2 to 3 doses through IV infusion over more than 30 minutes per day. For suspected infections in patients with pathogenic pneumonia, peritonitis, and neutropenia, administer 1 g (potency) intravenously every 8 hours. For cystic fibrosis and meningitis, administer 2 g (potency) intravenously every 8 hours.

Child administration

For bacterial meningitis in children over 3 months, administer 40 mg per kg body weight intravenously over 30 minutes every 8 hours depending on the susceptibility of the pathogen and the patient's condition, type of infection.

This medication should not be used in patients who have previously experienced shock reactions to it. Additionally, in patients taking sodium valproate, this medication may lower the blood concentration of valproate, increasing the risk of recurrence of seizures, so it should not be administered together. Patients with a history of hypersensitivity to this medication or its components, as well as those who have shown serious allergic reactions to other carbapenem or beta-lactam antibiotics, should not receive this medication. Patients with a history of allergic constitution or frequent symptoms such as asthma, rash, etc. should use it with caution, and those with renal impairment may require dose adjustment due to prolonged retention of the drug in the body and the potential for central nervous system side effects. Patients with epilepsy or central nervous system diseases, patients with very poor liver function, elderly individuals, malnourished persons, and infants under 3 months old should be used carefully. During administration, careful observation for allergic symptoms such as shock, rash, itching, urticaria, as well as blood abnormalities, liver or kidney dysfunction, severe diarrhea, and central nervous system abnormal symptoms is necessary. Particularly, severe skin reactions, rhabdomyolysis, and cardiovascular abnormalities can occur rarely, so if any abnormal symptoms appear, administration should be immediately discontinued and appropriate treatment should be provided. To prevent the emergence of resistant bacteria, it is important to conduct susceptibility testing and to administer for only the required minimum duration, while paying special attention to liver function tests and abnormal reactions such as rash during long-term use. Caution is required when using this medication together with certain drugs like probenecid, anticonvulsants, and hormonal contraceptives due to potential interactions, and when used with warfarin, the thrombo-prophylactic effect may alter, necessitating frequent blood tests. Women who are pregnant or may become pregnant should have careful consideration regarding the administration of this medication, and breastfeeding should be avoided during its use. The safety and efficacy of this medication have not been established in infants under 3 months of age, so its use should be approached with caution. Elderly patients may experience side effects more easily due to decreased bodily function and may have an increased risk of bleeding due to vitamin K deficiency, so dosage and administration intervals should be adjusted and carefully monitored. During tests, some urine glucose tests or direct Coombs tests, and urobilinogen tests may yield false positive results, so care should be taken when interpreting test results. This medication must be used promptly after dissolution and is only to be used as an intravenous injection. Lastly, this medication may have cross-reactivity with other beta-lactam antibiotics, so special caution is warranted for patients with a previous allergy to beta-lactam drugs.

Serious side effects

• Shock, anaphylaxis, urticaria, angioedema, severe allergic reactions
• Severe rashes, blisters, skin peeling, mucosal pain in the mouth/eyes, toxic epidermal necrolysis (Lyell's syndrome), mucocutaneous syndrome (Stevens-Johnson syndrome), DRESS syndrome, erythema multiforme, acute generalized exanthema pustulosis (AGEP)
• Breathing difficulties, asthma, pleural effusion, interstitial pneumonia, pulmonary edema, PIE syndrome and other respiratory issues
• Liver abnormalities (acute liver failure

Mild side effects

Oral discomfort, wheezing, dizziness, changes in stool, tinnitus, sweating, heat sensation, erythema, itching, fever, flushing, general rash, angioedema, hematologic abnormalities (pancytopenia, agranulocytosis, hemolytic anemia, hypochromic anemia, leukopenia, neutropenia, eosinophilia, thrombocytopenia or thrombocytosis, lymphocytosis, decrease in hemoglobin, increase in basophils, increase in atypical lymphocytes, decrease in red blood cells, decrease in hematocrit, hypokalemia

This medication should be stored in a sealed container to prevent air ingress, and it is best to store it at room temperature between 1 and 30 degrees Celsius. This storage condition helps to maintain the effectiveness of the medication.

Appearance

A vial filled with white to light yellow crystalline powder

Package unit

10 vials/box